| Identification | Back Directory | [Name]
A-674563 | [CAS]
552325-73-2 | [Synonyms]
CS-258
A-674563
A-674563 /A674563
A-674563 USP/EP/BP
A-674563;A 674563; A674563
(S)-1-(5-(3-Methyl-1H-indazol-5-yl)pyridin-3-yloxy)-3-phenylpropan-2-amine
(2S)-1-(5-(3-methyl-1H-indazol-5-yl)pyridin-3-yloxy)-3-phenylpropan-2-amine
Benzeneethanamine, α-[[[5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (αS)-
(alphaS)-alpha-[[[5-(3-Methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]benzeneethanamine
(alphaS)-alpha-[[[5-(3-Methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]benzeneethanamine A-674563
A-674563
(alphaS)-alpha-[[[5-(3-Methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]benzeneethanamine
A-674563 /A674563 | [Molecular Formula]
C22H22N4O | [MDL Number]
MFCD11840461 | [MOL File]
552325-73-2.mol | [Molecular Weight]
358.44 |
| Chemical Properties | Back Directory | [Boiling point ]
624.4±55.0 °C(Predicted) | [density ]
1.229 | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; ≥23.8 mg/mL in H2O; ≥4.9 mg/mL in DMSO | [form ]
solid | [pka]
13.43±0.40(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
A-674563 inhibits Akt1, PKA and CDK2 with Ki of 11 nM, 16 nM and 46 nM, respectively. | [Biological Activity]
a-674563 is a potent and selective akt1 inhibitor with ic50 value of 14 nm. a-67453 also inhibited pka and cdk2 with ic50 value of 16 nm and 46 nm.akt, also known as protein kinase b, is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration.in miapaca-2 cells treated with a-674563 for 48 hour, it slowed the tumor cell proliferation (ec50 = 0.4 μm). in sts cells, phosphorylation of gsk3 and mdm2 was prominently reduced by a-674563 treatment. [1] akt inhibition-induced g2 cells cycle arrest and apoptosis were also observed in a563-treated sts cells. [2]in scid mice carrying established pc-3 tumors, administration of a-674563 at 40 mg/kg per day for 21 days, combined with administration of paclitaxel at 15 mg/kg per day on days 20.24.28, increased the efficacy of paclitaxel compared with paclitaxel monotherapy. [1] a563 also significantly blocked ht1080 xenograft growth in nude mice. [2] | [in vivo]
A-674563 (40 mg/kg/d, p.o.) shows no significant monotherapy activity, but the efficacy of the combination therapy (A-674563+paclitaxel) is significantly improved in the PC-3 prostate cancer xenograft model. A-674563 (20, 100 mg/kg) increases plasma insulin in an oral glucose tolerance test[1].
A563 (20 mg/kg/bid; p.o.) exhibits slow tumor growth and a significant difference in tumor volume without significant weight loss of mice. A563-treated tumors express increased levels of GADD45α and decreased levels of PCNA (a nuclear marker for proliferation). Additionally, TUNEL assay staining levels (marker for apoptosis) increase in the A563-treated specimens[2].
A-674563 (25, 100 mg/kg, lavage daily) potently inhibits A375 xenograft growth in mice[3].
A-674563 (15, 40 mg/kg) injection inhibits U937 xenograft in vivo growth, and improves mice survival[4]. | [target]
Akt1 | [IC 50]
Akt1: 11 nM (Ki); PKA: 16 nM (Ki); CDK2: 46 nM (Ki); GSK3β: 110 nM (Ki); ERK2: 260 nM (Ki); PKCδ: 360 nM (Ki); RSK2: 580 nM (Ki); MAPK-AP2: 1.1 μM (Ki); PKCγ: 1.2 μM (Ki); Chk1: 2.6 μM (Ki); CK2: 5.4 μM (Ki); SRC: 13 μM (Ki) | [References]
1. luo y, shoemaker ar, liu x et al. potent and selective inhibitors of akt kinases slow the progress of tumors in vivo. mol cancer ther. 2005 jun;4(6):977-86.2. zhu qs, ren w, korchin b et al. soft tissue sarcoma cells are highly sensitive to akt blockade: a role for p53-independent up-regulation of gadd45 alpha. cancer res. 2008 apr 15;68(8):2895-903. |
|
| Company Name: |
T&W GROUP
|
| Telephone: |
021-61551611 13296011611 |
| Website: |
www.trustwe.com/ |
|